Studies have shown that CD16-positive, non-classical, monocyte count, including monocytes expressing the type II interferon inducible marker, CXCL10, was higher in SSc patients when compared to healthy controls and was associated with an increased risk of fibrotic manifestations., e.g., ILD and a higher modified Rodnan skin score (24–26). Here, CXCL10 is linked to interstitial lung disease.